Our Firm continues to hear from individuals who allegedly experienced side effects caused by the Rejuvenate and ABG II hip stems.
New York, NY (PRWEB) June 29, 2014
Bernstein Liebhard LLP notes the scheduling of a Stryker recall (http://www.strykerhiprecallclaims.com/) status conference in New Jersey’s Bergen County Superior Court, where a consolidated metal hip litigation now includes over 1,500 claims.
According to a Calendar posted on the Court’s website, a meeting has been scheduled for August 4, 2014 at 1:00 p.m., at which time parties involved in the proceeding will discuss claims filed over the Stryker Rejuvenate and ABG II modular-neck hip stems. Among other things, court documents indicate that cases involved in the litigation similarly allege pain, swelling, and symptoms of metallosis caused by the metal hip replacements, which were subject to a recall which was announced by the U.S. Food and Drug Administration (FDA) on July 6, 2012. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)
“We are pleased to see further progress in the New Jersey litigation involving Stryker lawsuits, as our Firm continues to hear from individuals who allegedly experienced side effects caused by the Rejuvenate and ABG II hip stems,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case evaluations to individuals who may have been injured by the Stryker Rejuvenate and ABG II metal hips.
Stryker Hip Lawsuits
According to a Case List updated on June 18th, a total of 1,581 Stryker lawsuits have now been filed in the New Jersey litigation on behalf of individuals who received the Stryker Rejuvenate and ABG II modular-neck hip stems. These metal hip replacements were subject to a July 2012 recall issued after Stryker Orthopaedics became aware of their potential to fret and corrode at the modular-neck junction. In turn, patients may experience pain, swelling and other adverse tissue reactions, the manufacturer said in its recall announcement. In the months following Stryker’s Rejuvenate and ABG II hip recall, the company advised on its website that all patients fitted with one of these devices undergo routine medical screening to monitor for signs of premature device failure, whether or not they are experiencing symptoms.*
Additionally, court documents filed on June 16th show at least 970 Stryker Rejuvenate and ABG II hip lawsuits now pending in a federal litigation underway in the U.S. District Court, District of Minnesota. Claims included in this proceeding similarly accuse Stryker of failing to adequately warn about side effects that may stem from its metal hip replacements, which were defectively designed. Plaintiffs similarly allege chronic pain, osteolysis, tissue necrosis, metallosis and other complications associated with premature failure of the hip. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)
Individuals who were allegedly harmed by the Rejuvenate and ABG II hip stems may be eligible to file their own Stryker hip lawsuit. To learn more about the Stryker hip recall, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys’ fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP